These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32439481)

  • 41. Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.
    Beringer PM; Bensman TJ; Ho H; Agnello M; Denovel N; Nguyen A; Wong-Beringer A; She R; Tran DQ; Moskowitz SM; Selsted ME
    J Antimicrob Chemother; 2016 Jan; 71(1):181-8. PubMed ID: 26433781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synergistic antibacterial and anti-biofilm activities of resveratrol and polymyxin B against multidrug-resistant Pseudomonas aeruginosa.
    Qi L; Liang R; Duan J; Song S; Pan Y; Liu H; Zhu M; Li L
    J Antibiot (Tokyo); 2022 Oct; 75(10):567-575. PubMed ID: 35999263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
    Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model.
    Elkhatib W; Noreddin A
    Microb Drug Resist; 2014 Dec; 20(6):575-82. PubMed ID: 25050970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B.
    Bratu S; Quale J; Cebular S; Heddurshetti R; Landman D
    Eur J Clin Microbiol Infect Dis; 2005 Mar; 24(3):196-201. PubMed ID: 15772821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor.
    Cho DY; Lim DJ; Mackey C; Weeks CG; Peña Garcia JA; Skinner D; Grayson JW; Hill HS; Alexander DK; Zhang S; Woodworth BA
    Int Forum Allergy Rhinol; 2018 May; 8(5):577-583. PubMed ID: 29412515
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers.
    Howard JJ; Sturge CR; Moustafa DA; Daly SM; Marshall-Batty KR; Felder CF; Zamora D; Yabe-Gill M; Labandeira-Rey M; Bailey SM; Wong M; Goldberg JB; Geller BL; Greenberg DE
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137807
    [No Abstract]   [Full Text] [Related]  

  • 48. Polymicrobial Ventilator-Associated Pneumonia: Fighting In Vitro Candida albicans-Pseudomonas aeruginosa Biofilms with Antifungal-Antibacterial Combination Therapy.
    Rodrigues ME; Lopes SP; Pereira CR; Azevedo NF; Lourenço A; Henriques M; Pereira MO
    PLoS One; 2017; 12(1):e0170433. PubMed ID: 28114348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
    Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of Pexiganan Combination with Tigecycline in a Mouse Model of Pseudomonas aeruginosa Sepsis.
    Cirioni O; Simonetti O; Morroni G; Brescini L; Kamysz W; Kamysz E; Orlando F; Pierpaoli E; Caffarini M; Orciani M; Agostinelli C; Offidani A; Provinciali M; Giacometti A
    Curr Top Med Chem; 2018; 18(24):2127-2132. PubMed ID: 30569865
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections.
    Chojnacki M; Philbrick A; Wucher B; Reed JN; Tomaras A; Dunman PM; Wozniak RAF
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30420484
    [No Abstract]   [Full Text] [Related]  

  • 52. In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa.
    Ma W; Li J; Wang D; Yu C; Sun S
    Lett Appl Microbiol; 2019 Sep; 69(3):198-203. PubMed ID: 31236975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased therapeutic efficacy of combination of azithromycin and ceftazidime on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection.
    Wang X; Cai Y; Xing H; Wu W; Wang G; Li L; Chen J
    BMC Microbiol; 2016 Jun; 16(1):124. PubMed ID: 27341798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
    Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
    Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.
    Bui KQ; Banevicius MA; Nightingale CH; Quintiliani R; Nicolau DP
    J Antimicrob Chemother; 2000 Jan; 45(1):57-62. PubMed ID: 10629013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an
    Montero M; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Angulo-Brunet A; Padilla E; Prim N; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32041712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections.
    Tascini C; Gemignani G; Ferranti S; Tagliaferri E; Leonildi A; Lucarini A; Menichetti F
    J Chemother; 2004 Jun; 16(3):282-7. PubMed ID: 15330326
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro antimicrobial activity of imipenem plus amikacin or polymyxin B against carbapenem-resistant Pseudomonas aeruginosa isolates.
    Wilhelm CM; Nunes LS; Martins AF; Barth AL
    Diagn Microbiol Infect Dis; 2018 Oct; 92(2):152-154. PubMed ID: 29891185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Novel, Broad-Spectrum Antimicrobial Combination for the Treatment of Pseudomonas aeruginosa Corneal Infections.
    Chojnacki M; Philbrick A; Scherzi T; Pecora N; Dunman PM; Wozniak RAF
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.